94 results about "Proteomic Profile" patented technology

The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns a comprehensive proteomic analysis of human amniotic fluid (AF) and cervical vaginal fluid (CVF), and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, pre-term labor, and/or chromosomal defects. The invention further concerns the identification of biomarkers and groups of biomarkers that can be used for non-invasive diagnosis of various pregnancy-related disorders, and diagnostic assays using such biomarkers.

The invention provides methods for multiplex analysis of biological samples of formalin-fixed tissue samples. The invention provides for a method to achieve a multiplexed, multi-staged plurality of Liquid Tissue preparations simultaneously from a single histopathologically processed biological sample, where the protocol for each Liquid Tissue preparation imparts a distinctive set of biochemical effects on biomolecules procured from histopathologically processed biological samples and which when each of the preparations is analyzed can render additive and complementary data about the same histopathologically processed biological sample.

The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells/tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc.

The present invention is directed to systems and methods for assessing the success of the transplant of a cell, tissue, or organ before and after transplant. Protein array technology is used to obtain a biomarker pattern for the cell, tissue, or organ that is being considered for transplant or that has been transplanted. Samples for the identification of biomarkers and biomarker patterns are obtained from the cell, tissue or organ itself, or from a body fluid of the donor or recipient. Sample biomarker data are compared to reference biomarker data obtained from donors, recipients or cells, tissues or organs that have been transplanted. Correlation of a sample biomarker pattern with the reference biomarker pattern, where transplant outcome for the samples used for the reference biomarkers is known, permits a suggested treatment determination. A computerized system to identify the condition of transplant before or after implantation is also provided.

Methods of determining whether a sample includes one or more analytes, particularly proteinaceous analytes, of interest are provided. In the subject methods, an array of binding agents, where each binding agent includes an epitope binding domain of an antibody, is contacted with the sample. In many embodiments, contact occurs in the presence of a metal ion chelating polysaccharide, e.g., a pectin. Following contact, the presence of binding complexes on the array surface are detected and the resultant data is employed to determine whether the sample includes the one or more analytes of interest. Also provided are kits, systems and other compositions of matter for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including proteomic applications such as protein expression analysis, e.g., differential protein expression profiling.

This invention related to methods useful in the labeling of multiple polypeptide samples and subsequent analysis of these samples by mass spectrometry, particularly in the high throughput proteomic setting.

Provided are protein microarrays, their manufacture, use, and application. Protein microarrays in accordance with the present invention are useful in a variety preoteomic analyses. Various protein arrays in accordance with the present invention may immobilize large arrays of proteins that may be useful for studying protein-protein interactions to improve understanding of disease processes, facilitating drug discovery, or for identifying potential antigens for vaccine development. The protein array elements of the invention are native or modified proteins (e.g., antibodies or fusion proteins). The protein array elements may be attached directly to a organic functionalized mirrored substrate by a binding reaction between functional groups on the substrate (e.g., amine) and protein (e.g., activated carboxylic acid). Techniques for chemical blocking of the arrays are also provided. The invention contemplates spotting of array elements onto solid planar substrates, labeling of complex protein mixtures, and the analysis of protein binding to the array. The invention also enables the enrichment or purification, and subsequent sequencing or structural analysis of proteins that are identified as differential by the array screen. Kits including protein-binding microarrays for proteomic analysis in accordance with the present invention are also provided.

The invention provides a polypeptide marker for early diagnosis of diabetes mellitus. The operating method comprises the following steps: establishing an in-vitro simulated glycosylation model by selecting human peripheral blood high-abundant protein HAS, performing enzyme digestion under optimized conditions, performing 18O marking on a blank control group sample subjected to enzyme digestion, mixing the blank control group sample with a reaction group sample subjected to parallel treatment by using 16O according to a volume percent of 1:1, and performing HPLC/ESI-TOFMS detection. According to quantitative analysis of HSA peptide fragments, a peptide fragment, which is the most difficultly modified by glucose and is shown as SEQ ID NO.1, serves as an internal standard peptide fragment, a ratio of a peptide fragment which is easily subjected to glycosylation modification to the peak area of the internal standard peptide fragment is used for measuring the glycosylation modification degree of a glucose sensitive peptide, and according to a proteomics method, three peptide fragments, namely FKDLGEENFK, LDELRDEGK and KVPQVSTPTLVEVSR are finally discovered to serve as biological markers to be used for early diagnosis of diabetes mellitus.

The present invention provides proteomic techniques that extend sensitive and quantitative analysis of proteins to post-translational modifications. Protein micro-arrays and/or multiplex coded-microbeads are used in combination with multilayered affinity interaction detection (MAID) methods that permit high throughput analysis of cellular protein modifications and functional protein interactions.

The invention discloses a method of researching the change of a proteome of rice responding rice blast bacterial infection through an iTRAQ technology and belongs to the field of plant biotechnology. The method includes following steps: A. extracting a plant materials and leaf protein; B. performing further FASP enzymolysis, peptide fragment marking, SCX classification and LC-MS analysis to the protein sample obtained in the step A; C. performing data query and quantitative analysis to the result after the LC-MS analysis to obtain the change situation of the whole proteome during an interaction process between rice and rice blast bacteria. The method can quickly and effectively screening a candidate gene relative to disease resistance of rice, can be used for researching the candidate gene relative to the disease resistance of the rice well with the proteomics researching method, iTRAQ, which is high-throughput and accurate, can be widely used for researching and developing the characters of plant disease resistance and breeding new plant varieties being strong in disease resistance with combination of the transgenic technology.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

The invention relates to a mass spectrometry calibration system that may be performed in real-time using the information contained within a sample without the addition of specific calibrants. When applied to a sample, such as a proteomic sample, the calibration system may identify the exact masses of peptides in the sample. The system involves the use of mathematical algorithms that iteratively estimate the error in the measurement and update the calibration parameters accordingly; thereby resulting in peptide mass identification.

Disclosed herein are systems and methods for determining metabolic pathway dynamics using time series multiomics data. In one example, after receiving time series multiomics data comprising time-series metabolomics data associated a metabolic pathway and time-series proteomics data associated with the metabolic pathway, derivatives of the time series multiomics data can be determined. A machine learning model, representing a metabolic pathway dynamics model, can be trained using the time series multiomics data and the derivatives of the time series multiomics data, wherein the metabolic pathway dynamics model relates the time-series metabolomics data and time-series proteomics data to the derivatives of the time series multiomics data. The method can include simulating a virtual strain of the organism using the metabolic pathway dynamics model.